The purpose of the study is to understand how well preterm infants tolerate RetinolX and to measure the levels of retinol in their blood. The study will involve infants who are born very early, between 22 and 29 weeks of pregnancy. The treatment will be given from the time they are born until they reach 36 weeks of what is called post-menstrual age, which is the age they would be if they were still in the womb.

Throughout the study, the infants will receive injections of RetinolX, and their blood will be tested to see how much retinol is present at different times. The study will also look at how safe the treatment is by checking for any side effects or changes in the infants’ health. The goal is to see if the treatment can help improve the infants’ lung condition without causing any harm.

The purpose of the study is to find out if giving azithromycin for six months can reduce the number of times children with these lung problems experience respiratory infections that get worse and need treatment. During the study, children will receive either azithromycin or placebo by mouth for a period of six months. The medicine comes as a liquid suspension that can be swallowed. Researchers will track how many times the children develop breathing problems that get worse during the treatment period, which are called respiratory exacerbations.

The study will also look at other important information such as how long these episodes of worsening breathing problems last, how many times children need to be admitted to the hospital, and how long those hospital stays are. Children participating in the study will be between zero and seventy-two months of age, which means from newborns up to six years old. All participating children will already be receiving care at specialized pediatric lung centers.

The purpose of the study is to see if giving an extra dose of caffeine citrate before removing the breathing tube can improve the chances of successful extubation. The study will monitor the need for reintubation, which means putting the breathing tube back in if the baby struggles to breathe on their own. It will also look at other factors like the frequency of breathing pauses (apneas), side effects such as increased heart rate or blood pressure, and any digestive issues. Additionally, the study will observe the development of conditions like necrotizing enterocolitis, a serious intestinal disease, and the progression of brain-related issues such as intraventricular hemorrhage or periventricular leukomalacia.

The trial will follow the participants over a period to assess their neurodevelopmental outcome, which refers to how well their brain develops and functions over time. The study aims to provide valuable insights into whether this additional caffeine citrate dose can help improve breathing outcomes and overall health in these vulnerable infants.

The purpose of the study is to see if the combination of Budesonide and Poractant Alfa can help prevent BPD in these very preterm infants. During the study, some infants will receive the combination treatment, while others will receive only the surfactant. The study will monitor the infants’ lung health and inflammation levels over time, using methods like lung ultrasound and checking for specific markers in their respiratory system. The safety of the treatment will also be closely observed, looking for any potential side effects or complications.

The study will follow the infants for a period of time to assess their lung development and overall health. This includes checking their need for oxygen and respiratory support, as well as evaluating their neurodevelopment at two years of age. The goal is to gather information that could lead to better treatments for preventing BPD in preterm infants, ultimately improving their long-term health outcomes.

The purpose of the study is to see if the automatic system can improve outcomes for these infants, such as reducing the risk of complications like retinopathy of prematurity (a serious eye condition), chronic lung disease, and necrotizing enterocolitis (a severe intestinal disease). The study will also look at the overall survival and development of the infants up to 24 months after their expected due date. The trial will involve monitoring the infants closely to see if the automatic system provides better results than the manual method.

Throughout the study, infants will receive oxygen through standard infant ventilators, which are machines that help them breathe. The trial will last until the infants are discharged from the hospital, and their development will be assessed at 24 months. This research is important to potentially improve the care and outcomes for extremely preterm infants by ensuring they receive the right amount of oxygen in a safe and effective way.

The purpose of this study is to determine if this treatment is safe for premature babies with BPD. The study will involve giving the treatment to babies who are born at or before 28 weeks of pregnancy and weigh 1250 grams or less. These babies will receive the treatment multiple times over a period of up to six weeks. The researchers will closely monitor the babies for any side effects or reactions to the treatment.

Throughout the study, the health of the babies will be carefully observed, especially their lung condition and overall development. The researchers will also look at how the treatment affects certain markers in the body that are related to inflammation and lung damage. The study aims to provide valuable information about the safety and potential benefits of using these special cells to help treat BPD in premature infants.

The purpose of the study is to compare the effectiveness of zelpultide alfa combined with the standard care against the standard care plus a placebo, which is a treatment that looks like the real one but has no active ingredients. The trial will involve very premature babies who are at high risk of developing BPD. These babies will receive either the new treatment or the placebo, in addition to the usual care they would normally receive. The study will monitor the babies to see if the new treatment helps reduce the occurrence of severe BPD or death by the time they reach 36 weeks of age, which is a common milestone for assessing lung health in premature infants.

Throughout the study, researchers will also look at other factors, such as the number of days the babies can breathe without the help of a ventilator and the overall survival rate by the 36-week mark. The trial is designed to provide valuable information on whether zelpultide alfa can offer additional protection for the lungs of these vulnerable infants, potentially leading to better outcomes and fewer complications related to BPD.

The purpose of the study is to assess the safety and effectiveness of EXOB-001 in preventing BPD in newborns who are born very early. The study is divided into two phases. In the first phase, the focus is on understanding the immediate and short-term safety of the treatment when given through the windpipe. In the second phase, the study will look at how well the treatment works in reducing the severity of BPD compared to the saline solution.

Participants in the study will receive the treatment through a method called intratracheal administration, which means it is delivered directly into the windpipe. The study will monitor the newborns until they reach 36 weeks of what is called postmenstrual age, which is the age of the baby calculated from the mother’s last menstrual period. The trial aims to find out if EXOB-001 can help reduce the severity of BPD and improve the health outcomes of these vulnerable newborns.

The study will compare the effects of OHB-607 with the standard care that is usually given to premature babies. Participants in the study will be randomly assigned to receive either the new treatment or the standard care. The study will monitor the babies’ health and development over a period of time to see if the new treatment is safe and effective. The researchers will look at how many babies develop severe lung disease or other complications, and they will also track the overall health and growth of the babies involved in the study.

Throughout the study, the health of the babies will be closely monitored by healthcare professionals. The study aims to provide valuable information on whether OHB-607 can reduce the risk of severe lung disease in extremely premature infants, potentially leading to better outcomes for these vulnerable patients. The study will continue to gather data until the babies reach a certain age, ensuring a comprehensive understanding of the treatment’s impact.